ProKidney Corp (PROK) - Company Total Revenue

While the success of ProKidney Corp. (PROK) depends on the outcomes of the REACT trials and patient recruitment rates, general market cycles have little impact on this biotech. The company's aggregate realization dynamics clearly demonstrate the current scale of operations, where the indicator value stands at 0.00. Meanwhile, the early stage of cellular method development requires strict cost control, although current funds are sufficient.

PROK ProKidney Corp: Company Revenue in the range 04/28/2023 - 11/14/2026

Analytical breakdowns for ProKidney Corp.

- current price and projected stock value:

Share Price ProKidney Pharma|PROK - Analyst Consensus Forecast

- market capitalization indicators:

Market Value ProKidney Corp.|PROK - Real Price to Acquire Entire Company

- book value of equity indicators:

Net Asset Value per Share ProKidney|PROK - Company Book Value|Market Capitalization to Net Assets prokidney.com|PROK - Aggregate Company Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

PROK - Company Net Income|Net Profit Forecast ProKidney Corp.|PROK - P/E Multiple|Projected Price to Earnings Ratio prokidney.com|PROK - Price/Earnings to Growth Multiple|Company Value to EBITDA ProKidney Corp.|PROK - Operating profit before deduction of amortization|Earnings per share for the trailing year ProKidney|PROK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months prokidney.com|PROK - Earnings per share growth in current year|Expected net earnings per share growth next year ProKidney Corp.

- sales volume and revenue indicators:

PROK - Company Revenue|Company Future Revenue ProKidney Pharma|PROK - Price-to-Revenue Ratio|Future Price to Revenue ProKidney Corp.

Comprehensive company analysis:PROK, ProKidney Pharma

The operational success of ProKidney Corp. (PROK) depends on progress in kidney cell therapy. This metric aggregates daily revenue, transforming cash flow into a measure of market resilience. It gauges the business's ability to generate income during recessions, revealing hidden risks of losing competitiveness. For a biotech startup with advance market confidence, this serves as an indicator of the model's viability. By analyzing the sales volume trajectory of ProKidney Corp. (PROK), an investor captures real consumer demand.

Key competitors